Pharmaceutical composition for treating osteoarthritis, preparation method, application and method for preparing phryma leptostachya extract
Through the combination of Y27632, sodium hyaluronate and bone-permea extract, the problem of limited effects of existing osteoarthritis treatment methods has been solved, and the effect of significantly reducing arthritis, protecting cartilage tissue and improving joint structure has been achieved, showing that more Excellent treatment of osteoarthritis.
Patent Information
- Application Number
- CN202310566625.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-18
- Publication Date
- 2024-11-22
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing treatments for osteoarthritis such as NSAIDs and intra-articular sodium hyaluronate injection have limited effects, and gastrointestinal and cardiovascular adverse events are present. No effective drugs can effectively alleviate arthritis, protect cartilage tissue and relieve symptoms.
A pharmaceutical composition is used, including Y27632, sodium hyaluronate and bone-permea extract, through synergistic action, significantly alleviates articular periosteum inflammation, protects cartilage tissue, reduces cartilage damage and relieves symptoms of osteoarthritis. Among them, the extract of the permeabilis extract is prepared by microwave extraction. The main active ingredients are ethyl palmitate and palmitate. Combined with acid-base regulators, osmotic pressure regulators and antibacterial agents, to form a liquid agent or injection solution for oral administration. , external or intra-articular injection.
The therapeutic effect of this pharmaceutical composition is significantly better than that of a single drug, which can effectively improve joint load-bearing capacity, reduce periosteal inflammation, protect cartilage tissue, significantly improve joint structure, and significantly reduce Mankin’s score, indicating better therapeutic effects.
Smart Images

Figure CN118987059A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of medicine, and in particular relates to a pharmaceutical composition for treating osteoarthritis, a preparation method and use thereof, and a method for preparing a radix scutellariae extract. Background Art
[0002] Osteoarthritis (OA) is a chronic inflammatory disease that affects bones and articular cartilage and is common in the elderly. It is characterized by degeneration, destruction, and bone hyperplasia of articular cartilage. The essence of OA is the progressive destruction of articular cartilage and even loss of function. The knee joint is most commonly affected. The main symptoms are swelling, pain, and limited mobility of the knee joint.
[0003] The treatment of osteoarthritis should be based on the principle of stepwise and individualized treatment, with the goal of alleviating pain, improving or restoring joint function, improving the patient's quality of life, delaying disease progression, and correcting deformities. Topical nonsteroidal anti-inflammatory drugs (NSAIDs) are mainly recommended as the first-line treatment for knee osteoarthritis pain, but the analgesic effect is limited and cannot be used for a long time. For osteoarthritis patients with persistent pain symptoms or moderate to severe pain, oral NSAIDs are selected, including non-selective NSAIDs and selective cyclooxygenase 2 (COX2) inhibitors, but gastrointestinal and cardiovascular adverse events are common.
[0004] Injecting lubricants such as sodium hyaluronate into the knee joint to relieve symptoms is a common method, but the effect is limited. Relieving inflammation, protecting cartilage tissue, and reducing chondrocyte loss can effectively improve the tissue structure of the knee joint, thereby alleviating symptoms. Currently available drugs for osteoarthritis include sodium hyaluronate, glucosamine, analgesics, sodium hyaluronate, Chinese herbal compound drugs, etc. However, the efficacy of oral drugs such as sodium hyaluronate and some Chinese herbal compound drugs is uncertain; intra-articular injection of sodium hyaluronate can only temporarily relieve symptoms, and has no obvious effect on reducing joint inflammation and reducing cartilage damage. Therefore, there is currently no effective drug to achieve the above-mentioned therapeutic effects.
[0005] In order to explore the efficacy of drugs for treating osteoarthritis, it is very important to establish an osteoarthritis animal model. Currently, the osteoarthritis model induced by intra-articular injection of iodoacetate is widely recognized. The main manifestations are joint damage, cartilage destruction and joint inflammation.
[0006] Currently, there is still a need for effective drugs in the treatment of osteoarthritis. Summary of the invention
[0007] The present invention aims to provide a pharmaceutical composition for treating osteoarthritis, which can effectively reduce inflammation of the perichondrium, protect cartilage tissue, reduce cartilage damage and relieve symptoms of osteoarthritis. The pharmaceutical composition of the present invention has a significantly better efficacy than any one or any two of the three active pharmaceutical ingredients in the composition, and the three active pharmaceutical ingredients have a synergistic effect.
[0008] The first aspect of the present invention relates to a pharmaceutical composition comprising the following substances:
[0009] (a) 30-300 μg / ml Y27632:
[0010]
[0011] (b) 2-20 mg / ml sodium hyaluronate; and
[0012] (c) 20-100 mg / ml of Herba Lycopodii Herba Extract.
[0013] In a preferred technical solution, the Herba Lycopodii Flavescentis extract is prepared by microwave extraction.
[0014] In the preferred technical solution, the main active ingredients in the extract of Herba Lycopodii are ethyl palmitate and palmitic acid.
[0015] Wherein, in the extract of Herba Lycopodii, the content of ethyl palmitate is 5-40 wt %, preferably 14-31 wt %, more preferably 20-25 wt %; and
[0016] The content of palmitic acid is 2-32 wt %, preferably 10-22 wt %, more preferably 13-18 wt %.
[0017] In a preferred embodiment, in the pharmaceutical composition: the concentration of Y27632 is 35-200 μg / ml, more preferably 40-100 μg / ml, most preferably 45-60 μg / ml; the concentration of sodium hyaluronate is 4-18 mg / ml, more preferably 6-15 mg / ml, most preferably 8-12 mg / ml; and the concentration of the Herba Polygoni Multiflori extract is 30-80 mg / ml, more preferably 35-70 mg / ml, most preferably 40-60 mg / ml.
[0018] In a preferred embodiment, the pharmaceutical composition is administered orally, topically or by injection.
[0019] In a preferred embodiment, the pharmaceutical composition is a liquid and the solvent is water.
[0020] In a preferred embodiment, the pharmaceutical composition is administered by injection into a joint cavity of a subject.
[0021] In a preferred embodiment, the pharmaceutical composition further comprises one or more substances selected from the group consisting of: an acid-base regulator, an osmotic pressure regulator, a thickener, and an antibacterial agent.
[0022] In a preferred embodiment, wherein:
[0023] The acid-base regulator is selected from one or more of disodium hydrogen phosphate, sodium dihydrogen phosphate, potassium dihydrogen phosphate, dipotassium hydrogen phosphate, tartaric acid, acetic acid, sodium acetate, boric acid and its salts, borax, citric acid, and sodium citrate; the amount thereof is based on adjusting the pH to 4-9, preferably 6-8.5, and more preferably 7-8;
[0024] The osmotic pressure buffer is one or more of sodium chloride, boric acid, borax, and glucose; the amount thereof is based on adjusting the osmotic pressure to 200-400 mOsm / L, preferably 250-350 mOsm / L, more preferably 285-310 mOsm / L;
[0025] The thickener is one or more of methyl cellulose, polyvinyl alcohol, polyethylene glycol, dextran, carboxymethyl cellulose, carboxypropyl methyl cellulose, polyvinyl pyrrolidone, polypropylene alcohol, sodium hyaluronate, chitosan, and sodium hyaluronate; the amount thereof is based on adjusting the viscosity to 2-12 mps, preferably 5-10 mps, and more preferably 7-9 mps;
[0026] The antibacterial agent is selected from one or more of boric acid, ethylparaben, methylparaben, propylparaben, phenylmercuric acetate, sorbic acid, chlorobutanol, thiophene, benzalkonium chloride and benzalkonium bromide, and the content thereof is 0%-0.1% (w / v).
[0027] In a preferred embodiment, the pharmaceutical composition comprises the following substances:
[0028] (a) 50 μg / ml Y27632:
[0029]
[0030] (b) 10 mg / ml sodium hyaluronate;
[0031] (c) 50 mg / ml Herba Lycopodii extract; and
[0032] (d) sodium chloride, in an amount sufficient to adjust the osmotic pressure to 285-310 mOsm / L;
[0033] The balance is water.
[0034] The second aspect of the present invention relates to a method for preparing the pharmaceutical composition according to the first aspect of the present invention, comprising the following steps:
[0035] (1) adding Y27632, sodium hyaluronate and Herba Spermatorrhizae Radix to a solvent, preferably water for injection or physiological saline for injection, so that the concentration of Y27632 is 30-300 μg / ml, the concentration of sodium hyaluronate is 2-20 mg / ml, and the concentration of Herba Spermatorrhizae Radix is 20-100 mg / ml;
[0036] (2) optionally adding one or more of an acid-base regulator, an osmotic pressure regulator, a thickener, and an antibacterial agent;
[0037] The amount of the acid-base regulator is based on adjusting the pH to 4-9, preferably 6-8.5, more preferably 7-8;
[0038] The amount of the osmotic pressure buffer is based on adjusting the osmotic pressure to 200-400 mOsm / L, preferably 250-350 mOsm / L, more preferably 285-310 mOsm / L;
[0039] The amount of the thickener is based on adjusting the viscosity to 2-12 mps, preferably 5-10 mps, more preferably 7-9 mps;
[0040] The content of the antibacterial agent is 0%-0.1% (w / v);
[0041] (3) The mixed solution is optionally sterilized and then aseptically packaged to obtain the pharmaceutical composition of the present invention.
[0042] The third aspect of the present invention relates to use of the pharmaceutical composition according to the first aspect of the present invention in preparing a medicament for treating osteoarthritis.
[0043] In a preferred embodiment, the osteoarthritis is acute gouty arthritis.
[0044] In a preferred embodiment, the osteoarthritis is classified by site, including but not limited to knee arthritis, hip arthritis, wrist arthritis, etc., and is classified by cause, including but not limited to autoimmune arthritis, infectious arthritis, gout, pseudogout, and joint inflammatory reactions such as joint injuries.
[0045] The components of the pharmaceutical composition of the present invention are described as follows:
[0046] Y27632: Chemical formula is It is an inhibitor of the ROCK signaling pathway. Studies have shown that Y27632 can significantly inhibit stem cell apoptosis caused by dissociation; promote bone formation by promoting the production of bone morphogenetic protein (BMP); induce chondroprogenitor cells to differentiate into chondrocytes; promote epidermal cell proliferation; and can be used to treat dry eye disease.
[0047] Sodium hyaluronate: A class of glycosaminoglycans that are covalently linked to proteins to form proteoglycans. Clinical studies have shown that it can reduce pain in patients with osteoarthritis, improve joint function, reduce joint swelling and effusion, and prevent joint narrowing in the knee and hand joints.
[0048] Phryma leptostachya L.: A traditional Chinese medicine with the effects of dispelling wind and dampness, dispelling cold and relieving pain, promoting blood circulation and unblocking meridians, and resolving phlegm and relieving cough. It is mainly used to treat rheumatic arthralgia, stomach cold pain, traumatic injury, and cough with phlegm.
[0049] A method for preparing a herba scutellariae extract, comprising:
[0050] 1. Collect the whole herb of Radix Psoraleae after it has sprouted and grown for 200 days or longer. Wash it with clean water, dry it at 115-120℃ for 3-4h, and grind it into 200 mesh fine powder.
[0051] 2. Mix the fine powder of Herba Scutellariae Radix and 3L 70% ethanol by volume per 100g, adjust the pH to 2, extract at 62-67°C for 10-60min, extract 2-5 times, and use microwave irradiation with a microwave frequency of 2450-2500MHz, with a microwave power / ethanol volume ratio of 150-175w / L;
[0052] 3. Combine the solutions after each extraction, evaporate under reduced pressure in a water bath at 60-65°C under an atmospheric pressure of -0.1 to -0.2 MPa to obtain the extract of Herba Lycopodii.
[0053] In order to facilitate the understanding of the present invention, some terms of the present invention are explained or defined. Unless otherwise explained or defined, the scientific and technical terms used in conjunction with the present invention will have the meanings commonly understood by those of ordinary skill in the art.
[0054]
[0055] Beneficial effects of the present invention:
[0056] (1) The pharmaceutical composition of the present invention has the therapeutic effect of treating osteoarthritis, and can effectively reduce inflammation of the perichondrium, protect cartilage tissue, reduce cartilage damage, and relieve symptoms of osteoarthritis;
[0057] (2) The therapeutic effect of the pharmaceutical composition of the present invention is significantly better than the efficacy of any one or any two of the three pharmaceutically active components in the composition, and there is a synergistic effect between the three pharmaceutically active components. BRIEF DESCRIPTION OF THE DRAWINGS
[0058] Figure 1 The figure shows the weight-bearing capacity of the hind limbs of animals with MIA-induced knee arthritis, where * indicates p<0.01 compared with the model control group.
[0059] Figure 2 The results of HE staining of the cartilage sections of the animal's hind limb knee joint are shown (x200).
[0060] Figure 3 The results of safranin staining of the cartilage sections of the animal's hind limb knee joint are shown (x200).
[0061] Figure 4 The Mankin's score of the hind limb knee joint of MIA-induced knee arthritis animals is shown, where * indicates p<0.01 compared with the model control group. DETAILED DESCRIPTION
[0062] For a better understanding of the present invention, the present invention will be described in detail below in conjunction with embodiments and drawings. However, it should be understood that these embodiments and drawings are only provided to illustrate the present invention and are not intended to limit the present invention.
[0063] In the present invention, unless otherwise specified, all operations are carried out at room temperature and normal pressure.
[0064] Example 1
[0065] The present embodiment adopts the following process to prepare the Herba Lycopodii extract:
[0066] Select the herb produced in the Qinling Mountains in Shaanxi Province. After germination, let it grow for another 200 days. Harvest the whole herb and wash it with clean water. Dry it at 120°C for 4 hours, and grind it into 200 mesh fine powder for later use.
[0067] 100g of the above-mentioned Herba Polygoni Multiflori powder was mixed with 3L of 70% ethanol by volume, the pH was adjusted to 2, the extraction temperature was 65°C, the extraction time was 15min, the number of extractions was 4, and the whole process was subjected to microwave irradiation with a microwave frequency of 2450MHz and a microwave power of 550W.
[0068] The solutions after each extraction were combined and evaporated under reduced pressure in a water bath at 60°C under an atmospheric pressure of -0.1 MPa to obtain 30.5 g of Herba Spermatorrhizae extract in the form of brown powder. The main active ingredients of the Herba Spermatorrhizae extract, ethyl palmitate and palmitic acid, were found to contain 22% and 16% respectively.
[0069] Example 2
[0070] This example evaluates the therapeutic effect of the pharmaceutical composition of the present invention on acute gouty arthritis in rats induced by sodium iodoacetate (MIA).
[0071] Methods: After 6 mg of MIA dissolved in 50 ul of saline was injected into the right knee joint cavity of 48 male rats (weight 180-220 g), the rats were randomly divided into a model control group (0.9% saline), a Y27532 group (50 μg / ml), a sodium hyaluronate group (10 mg / ml), a Herba speranskiae extract group (prepared in Example 1) (50 mg / ml), a Y27532+sodium hyaluronate group (50 μg of Y27532 and 10 mg of sodium hyaluronate dissolved in each ml of saline), a sodium hyaluronate+herba speranskiae extract group (10 mg of sodium hyaluronate and 50 mg of Herba speranskiae extract dissolved in each ml of saline), a Y27532+herba speranskiae extract group (Y27532 dissolved in each ml of saline 50μg and 50mg of Herba Sophorae Flavescentis extract) and a combination group (50μg of Y27532, 10mg of sodium hyaluronate and 50mg of Herba Sophorae Flavescentis extract dissolved in each ml of normal saline), 6 rats in each group. One week later, 50μl of the corresponding therapeutic drug was injected into the joint cavity. Three times a week for three consecutive weeks. The difference in the weight-bearing of the bilateral hind limbs of rats in each group was observed to observe the joint injury. The animals were killed 3 days after the last administration. The joint specimens were fixed in 4% paraformaldehyde for 72 hours, decalcified in ethylenediaminetetraacetic acid (EDTA) solution for 2 weeks, and then embedded in paraffin. HE staining and safranin staining were performed. Photos were taken under an optical microscope to determine the condition of the joint tissue. According to the structure of articular cartilage, cartilage matrix, chondrocyte aggregation and number, tide line and other aspects, the Mankin's score was performed using a double-blind method. The highest score is 14 points and the lowest score is 0 points.
[0072] result:
[0073] 1. After 3 weeks of continuous administration, it was observed that the Y27632 group, the sodium hyaluronate group, the Herba scutellariae extract group, the Y27532+sodium hyaluronate group, the sodium hyaluronate+herba scutellariae extract group, the Y27532+herba scutellariae extract group and the combination group could improve the hind limb load-bearing capacity of the experimental rats to a certain extent, but the effect of the combination group was more significant, and the degree of improvement was better than that of the group treated with any one or any two of the three components in the combination ( Figure 1 ).
[0074] 2. HE staining results showed that 4 weeks after MIA modeling, the model control group had extensive perichondrium and cartilage damage, a large number of inflammatory cells infiltrated under the perichondrium, a sharp decrease in chondrocytes, and a decrease in cartilage thickness. The Y27632 group could reduce inflammatory infiltration under the perichondrium, the perichondrium was intact, and the cartilage thickness and the number of chondrocytes were significantly improved. The inflammatory cell infiltration under the perichondrium of animals in the sodium hyaluronate group and the Herba Polygoni Multiflori extract group was reduced, but the degree of cartilage destruction was not significantly reduced. The combination group significantly protected the rat perichondrium and reduced the inflammatory response. The number of chondrocytes and cartilage thickness were close to those of normal cartilage (ie, normal control) ( Figure 2 ).
[0075] 3. The results of safranin staining showed that the perichondrium of the model control group was severely damaged 4 weeks after MIA modeling. The Y27632 group retained part of the cartilage matrix, while the protective effect of the cartilage matrix of the animals in the sodium hyaluronate group and the Herba Lycopodii extract group was not obvious. The combination group significantly protected the cartilage matrix of rats ( Figure 3 ).
[0076] 4. The results of Mankin's score showed that Y27532 could reduce Mankin's score, indicating that Y27532 has a therapeutic effect on arthritis. However, the sodium hyaluronate group, the Herba scutellariae extract group, the Y27532+sodium hyaluronate group, the sodium hyaluronate+herba scutellariae extract group, and the Y27532+herba scutellariae extract group had no significant effect on improving Mankin's score. Y27532 combined with sodium hyaluronate and Herba scutellariae extract could further significantly reduce Mankin's score, indicating that the drug combination has a better therapeutic effect ( Figure 4 ).
[0077] Conclusion: Intra-articular injection of Y27632 can improve the load-bearing capacity of the lower limbs and the structure of the knee cartilage in rats with osteoarthritis, and the combined effect with sodium hyaluronate and Herba Scutellariae extract can further significantly increase the therapeutic effect. The pharmaceutical composition of the present invention can effectively reduce inflammation of the perichondrium, protect cartilage tissue, reduce cartilage damage and relieve symptoms of osteoarthritis. The therapeutic effect of the pharmaceutical composition of the present invention is significantly better than the efficacy of any one or any two of the three active pharmaceutical ingredients in the composition, and there is a synergistic effect between the three active pharmaceutical ingredients.
[0078] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Without departing from the spirit and scope of the present invention, the present invention may have various changes and improvements, and these changes and improvements will fall within the scope of the present invention to be protected. The scope of protection claimed in the present invention is defined by the attached claims and their equivalents. For those of ordinary skill in the art, it is necessary to make various other corresponding changes according to the technical scheme and technical concept of the present invention under the advice and professional guidance of clinicians to ensure the efficacy described in the present invention and the feasibility of other beneficial effects and schemes and compatibility listed in the specification, and all these changes should belong to the scope of protection of the claims of the present invention.
[0079] References
[0080] Joint Surgery Group of the Orthopaedic Branch of the Chinese Medical Association, Osteoarthritis Group of the Orthopaedic Branch of the Chinese Medical Doctor Association, National Clinical Research Center for Geriatric Diseases (Xiangya Hospital), et al., Guidelines for the Diagnosis and Treatment of Osteoarthritis in China (2021 Edition)[J]. Chinese Journal of Orthopaedics, 2021, 41(18): 1291-1314.
Claims
1. A pharmaceutical composition, characterized in that It contains the following substances: (a) 30-300 μg / ml Y27632; (b) 2-20 mg / ml sodium hyaluronate; and (c) 20-100 mg / ml of Herba Lycopodii Herba Extract.
2. The pharmaceutical composition according to claim 1, wherein: The concentration of Y27632 is 35-200 μg / ml, more preferably 40-100 μg / ml, and most preferably 45-60 μg / ml; The concentration of sodium hyaluronate is 4-18 mg / ml, more preferably 6-15 mg / ml, most preferably 8-12 mg / ml; and The concentration of the Herba Lycopodii extract is 30-80 mg / ml, more preferably 35-70 mg / ml, and most preferably 40-60 mg / ml.
3. The pharmaceutical composition according to claim 1, wherein the Herba Scutellariae Radix Extract is prepared by the following method: 1) Collecting the radix spatholobi, after germination, growing for 200 days or longer, harvesting the whole grass and washing it with clean water, drying it at 115-120° C. for 3-4 hours, and crushing it to obtain 200 mesh fine powder; 2) mixing 100 g of the above-mentioned Herba Spermatorrhizae uralensis powder with 3 L of 70% ethanol by volume, adjusting the pH to 2, extracting at 62-67° C. for 10-60 min, extracting 2-5 times, and irradiating with microwaves at a frequency of 2450-2500 MHz, with a microwave power / ethanol volume ratio of 150-175 w / L; 3) combining the solutions after each extraction, and evaporating under reduced pressure in a water bath at 60-65° C. under an atmospheric pressure of -0.1 to -0.2 MPa to obtain a Herba spatholobi extract.
4. The pharmaceutical composition according to claim 1, further comprising one or more substances selected from the group consisting of: an acid-base regulator, an osmotic pressure regulator, a thickener, and an antibacterial agent.
5. The pharmaceutical composition according to claim 4, wherein: The acid-base regulator is selected from one or more of disodium hydrogen phosphate, sodium dihydrogen phosphate, potassium dihydrogen phosphate, dipotassium hydrogen phosphate, tartaric acid, acetic acid, sodium acetate, boric acid and its salts, borax, citric acid, and sodium citrate; the amount thereof is based on adjusting the pH to 4-9, preferably 6-8.5, and more preferably 7-8; The osmotic pressure buffer is one or more of sodium chloride, boric acid, borax, and glucose; the amount thereof is based on adjusting the osmotic pressure to 200-400 mOsm / L, preferably 250-350 mOsm / L, more preferably 285-310 mOsm / L; The thickener is one or more of methyl cellulose, polyvinyl alcohol, polyethylene glycol, dextran, carboxymethyl cellulose, carboxypropyl methyl cellulose, polyvinyl pyrrolidone, polypropylene alcohol, sodium hyaluronate, chitosan, and sodium hyaluronate; the amount thereof is based on adjusting the viscosity to 2-12 mps, preferably 5-10 mps, and more preferably 7-9 mps; The antibacterial agent is selected from one or more of boric acid, ethylparaben, methylparaben, propylparaben, phenylmercuric acetate, sorbic acid, chlorobutanol, thiophene, benzalkonium chloride and benzalkonium bromide, and the content thereof is 0%-0.1% (w / v).
6. The pharmaceutical composition according to claim 1, comprising the following substances: (a) 50 μg / ml Y27632; (b) 10 mg / ml sodium hyaluronate; (c) 50 mg / ml Herba Lycopodii extract; and (d) sodium chloride, in an amount sufficient to adjust the osmotic pressure to 285-310 mOsm / L; The balance is water.
7. A method for preparing a pharmaceutical composition according to any one of claims 1 to 6, comprising the following steps: (1) adding Y27632, sodium hyaluronate and Herba Spermatorrhizae Radix to a solvent, preferably water for injection or physiological saline for injection, so that the concentration of Y27632 is 30-300 μg / ml, the concentration of sodium hyaluronate is 2-20 mg / ml, and the concentration of Herba Spermatorrhizae Radix is 20-100 mg / ml; (2) optionally adding one or more of an acid-base regulator, an osmotic pressure regulator, a thickener, and an antibacterial agent; The amount of the acid-base regulator is based on adjusting the pH to 4-9, preferably 6-8.5, more preferably 7-8; The amount of the osmotic pressure buffer is based on adjusting the osmotic pressure to 200-400 mOsm / L, preferably 250-350 mOsm / L, more preferably 285-310 mOsm / L; The amount of the thickener is based on adjusting the viscosity to 2-12 mps, preferably 5-10 mps, more preferably 7-9 mps; The content of the antibacterial agent is 0%-0.1% (w / v); (3) The mixed solution is optionally sterilized and then aseptically packaged to obtain the pharmaceutical composition of the present invention.
8. Use of the pharmaceutical composition according to any one of claims 1 to 6 in the preparation of a medicament for treating osteoarthritis.
9. The use according to claim 8, wherein the osteoarthritis is classified by site to include knee arthritis, hip arthritis and wrist arthritis, and is classified by etiology to include joint inflammatory reactions selected from the following: autoimmune arthritis, infectious arthritis, gout, pseudogout and joint injury.
10. A method for preparing a Herba Lycopodii extract, comprising: 1) Collecting the radix spatholobi, after germination, growing for 200 days or longer, harvesting the whole grass and washing it with clean water, drying it at 115-120° C. for 3-4 hours, and crushing it to obtain 200 mesh fine powder; 2) mixing 100 g of the above-mentioned Herba Spermatorrhizae uralensis powder with 3 L of 70% ethanol by volume, adjusting the pH to 2, extracting at 62-67° C. for 10-60 min, extracting 2-5 times, and irradiating with microwaves at a frequency of 2450-2500 MHz, with a microwave power / ethanol volume ratio of 150-175 w / L; 3) combining the solutions after each extraction, and evaporating under reduced pressure in a water bath at 60-65° C. under an atmospheric pressure of -0.1 to -0.2 MPa to obtain a Herba spatholobi extract.
